ArticleThe Australian journal of rural health2025
Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data.
Article in The Australian journal of rural health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data.The Australian journal of rural health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveExplore Parkinson's Disease (PD) related prescription patterns for people with PD living in metropolitan and non-metropolitan areas of New South Wales, Australia.
methodsExploratory, cross-sectional data linkage study. Participants were grouped according to geographic location and by age group: metropolitan or non-metropolitan; rural, regional, and remote. Prescription patterns were analysed using descriptive and inferential statistics.
designThe Sax Institute's 45 and Up Study data was linked to the Pharmaceutical Benefits Scheme (PBS) records (2004-2017) for all participants with PD.
settingRetrospective data exploration and analysis.
participants1648 participants who self-identified as having PD and voluntarily contributed to the 45 and Up longitudinal study.
main outcome measuresStatistical comparisons based on location were undertaken for the different groupings for PD-specific medications.
resultsSignificant differences in the proportions of PD-related medications are observed between locations. Significant differences in the proportions of PD-related medications are observed between locations. A higher proportion of levodopa and levodopa combinations is reported for major cities (75.5%) compared with the inner region (70.3%) and outer and remote regions (74.1%). Additionally, other PD-related medications in the non-metropolitan areas are proportionally higher than those reported for major cities. Analysis by age groups suggests large effect sizes for the 75-79 and 45-49 age groups, while medium and small effect sizes are reported for the 55-59 and 70-74 age groups, respectively.
conclusionInequities with best practice medication treatment for PD exist between metropolitan and non-metropolitan areas of NSW. Efforts are required to successfully bridge gaps. Upskilling GPs may provide one way to optimise therapy and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.